PharmaSGP expects net double-digit revenue and profit growth in 2022

DGAP-News: PharmaSGP Holding SE / Keyword(s): Forecast
PharmaSGP expects net double-digit revenue and profit growth in 2022
25.04.2022 / 07:30
The issuer is solely responsible for the content of this announcement.

PharmaSGP expects net double-digit revenue and profit growth in 2022

Gräfelfing, April 25, 2022 – After another record year, German pharmaceutical company PharmaSGP is targeting revenues of between €78m and €82m for fiscal year 2022, up from €65.3m the previous year, equating to expected growth at least 19.5%. PharmaSGP also expects to see a marked increase in adjusted earnings before interest, taxes, depreciation and amortization (adjusted EBITDA). The company is targeting a 30-33% revenue-based margin, representing an adjusted EBITDA range of between 23.4 and 27.1 million euros.

“With our international portfolio of leading branded products and pharmaceutical products suitable for chronic indications, including the areas of pain and sleep disorders, we are very well positioned in the healthcare market,” said Nathalie Weigand, Confident CEO. “In my opinion, the pharmaceutical industry and in particular the market for non-prescription drugs – for which there is no price maintenance – will benefit again this year from the increase in demographic development and the growth of the accompanying request,” Weigand continued.

CFO Michael Rudolf also highlighted the further expected increase in adjusted EBITDA margin: “We have implemented a business model with low fixed costs which has proven to be successfully transferable to other target markets. We focus on our core competencies and have outsourced the entire manufacturing and logistics process. This allows us to remain very disciplined on the cost side despite the expected substantial sales growth, so that we can maintain the adjusted EBITDA margin in a sustainable range above 30%,” said Rudolf.

Other possible acquisitions are not included in the forecasts. Natalie Weigand commented: “In the meantime, PharmaSGP has an easily scalable pan-European platform with established structures that allow new brands to be onboarded successfully and without complications. The integration of GSK’s portfolio shows that by realizing targeted acquisitions, we can create substantial value for our investors in a timely manner, so new acquisitions will remain a key part of our strategy going forward.”

CONTACT

cometis S.A.
Claude Krause
Phone: 49-611-20585528
Email: [email protected]

ABOUT PHARMASGP HOLDING SE

PharmaSGP is a leading consumer healthcare company with a diverse portfolio of over-the-counter (OTC) pharmaceuticals and other marketed healthcare products with a focus on the pharmaceutical distribution channel. These products are primarily based on natural active pharmaceutical ingredients with documented efficacy and few known side effects.

The Company’s primary brands cover chronic indications, including rheumatic pain, nerve pain and other age-related conditions. In Germany, PharmaSGP is the market leader in chemical-free systemic analgesics with its RubaXX brand families(R) for rheumatic pain and Restaxil(R) for nerve pain. In addition, PharmaSGP also offers leading products for sexual weakness and vertigo symptoms. Since the introduction of the first product in the current product portfolio in 2012, PharmaSGP has successfully established its business model in other European countries, including Austria, Italy, Belgium, Spain and France. In September 2021, the product portfolio was expanded by Baldriparan brands(R)Formigran(R)Spalt(R) and Kamol(R), thus also reinforcing or developing the pain and sleep disorder indications. The sales territory has been expanded to include Switzerland and Eastern Europe.

In 2021, PharmaSGP generated sales of €65.3 million with an adjusted EBITDA margin of 29.7%.

In order to further expand its competitive position, PharmaSGP plans to increase the number of indications covered by PharmaSGP’s product offering, increase PharmaSGP’s European footprint and accelerate its growth strategy, in particular by capitalizing on selected mergers and acquisitions opportunities.

25.04.2022 Broadcast of a Corporate News, transmitted by the DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP distribution services include regulatory announcements, financial/corporate news and press releases.
Archive at www.dgap.de